{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:11:59Z","timestamp":1784139119223,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.eururo.2009.09.038","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T04:17:01Z","timestamp":1254889021000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Bacillus Calmette-Gu\u00e9rin Is Superior to a Combination of Epirubicin and Interferon-\u03b12b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study"],"prefix":"10.1016","volume":"57","author":[{"given":"Milo\u0161","family":"Duchek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Jahnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddvar","family":"Mestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverker","family":"Hellsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Uno","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2009.09.038_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1464-410X.1995.tb00759.x","article-title":"A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder","volume":"76","author":"Raitanen","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/00365590600744238","article-title":"Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001","volume":"40","author":"Gardmark","year":"2006","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2009.09.038_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.eururo.2008.06.062","article-title":"Is maintenance bacillus Calmette-Gu\u00e9rin really necessary?","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2009.09.038_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2009.09.038_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2009.09.038_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809010008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283809010008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:02:01Z","timestamp":1759582921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283809010008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0302283809010008"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2009.09.038","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Gu\u00e9rin Is Superior to a Combination of Epirubicin and Interferon-\u03b12b in the Intravesical Treatment of Patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2009.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}